Genero Pharmaceuticals: Your Trusted CDMO Partner for Dermatology
pharmatechoutlook

Genero Pharmaceuticals: Your Trusted CDMO Partner for Dermatology

Alfons Sindupranata, President Director, Derma Global Ventura, Genero PharmaceuticalsAlfons Sindupranata, President Director, Derma Global Ventura
With a surface area of over 21 square feet that accounts for almost 10 percent of the body weight, the human skin is the outer covering of the body and the largest organ of the integumentary system. A healthy skin not only adds to the appearance of an individual but also maintains the right metabolic and hormonal balance of the human body. The melanin pigment in the skin protects us from the harmful UVA and UVB rays that cause premature ageing, pigmentation, and even fatal diseases like skin cancer. Taking good care of the skin thus goes without saying. Keeping this in mind, dermatological companies are improvising their clinical formulations every day to help people restore and maintain healthy skin. And, in that endeavor, a name that always stands out as one of the mavens in the dermatology world is Indonesia-based Genero Pharmaceuticals.

Being a micro-enterprise of the Derma Global Ventura (DGV) group, Genero has a comprehensive understanding of the various facets related to dermatology. This extensive industry know-how has been helping the company provide leading-edge skin solutions for the last 20 years. Today, Genero is conquering the entire SEA market with its semi-solid and liquid skin formulations. “We collaborate with more than 170 dermatologists to develop skin solutions that solve the concerns of people belonging to any age or gender,” mentions Alfons Sindupranata, president director of Derma Global Venture.

Notably, Genero is not just an R&D and manufacturing organization that has an idle capacity that can be utilized by other pharma companies. Instead, Genero is a full-fledged CDMO organization—a domain that is still in its nascent stages in Indonesia. “So far in SEA, we do not see any other CDMO who has long experiences of developing and manufacturing high-quality semi-solid and liquid pharma product,” expresses Alfons Sindupranata. At the core of this success is the company’s relentless focus to strengthen its advanced manufacturing processes, and hone its human capital expertise for delivering on its commitment to exceptional service.

We do not use a one-size-fits-all stratagem; instead, each of our clients’ requirements is unique for us. We believe in establishing strong relationships with our customers.


So, how is Genero steering ahead of its competition? The answer lies in its superior integrated services: PHARMACEUTICA, SKINPROOF, FORMULATICA, QUALITICA, and COSMECEUTICA, which conducts multiple clinical trials to ensure the efficacy and safety of the dermatology products formulated. From protocol design, development, and consultation to data and statistical analysis to compliance and regulatory procedures, Genero provides top-quality clinical formulations to its clients. Alongside, through its quality management system, Genero ensures to deliver standard products and proper documentation relevant to clinical research activities. Owing to its extensive portfolio, today, Genero has emerged as the reliable one-stop solution for its clients in the dermatology domain.

Besides contract manufacturing services, Genero also provides several other services and solution to its clients. These services include product formulation, analytical method and packaging development, product stability testing, pilot scale and process validation, product registration until commercial production, and sharing of R&D, QC lab and production facilities, among others.

What makes Genero a cut above the rest is its flexible, customer-centric partnership approach. “We do not use a one-size-fits-all stratagem; instead, each of our clients’ requirements is unique for us. We believe in establishing strong relationships with our customers,” mentions Budihardjo Chandra, CEO at Genero Pharmaceuticals. To further illustrate how its solutions are benefitting its clients, Chandra cites a case study where Genero has helped one of a company overcome the long time variation result of their critical quality parameter measurement. By effectively identifying the root cause, Genero utilized its expertise and experience in dosage form knowledge and eradicated the errors with its innovative corrective actions.

With such success stories inspiring its proficient team to evolve its products and infrastructure daily, Genero aims to further improve its services by expanding its facility in the next two years in terms of capabilities and facilities. By continuing to deliver quality-driven standard solutions to its customers, Genero is determined to remain customer’s priority pick in the years to come!
Share this Article:
Genero Pharmaceuticals

Company
Genero Pharmaceuticals

Headquarters
Jakarta, Indonesia

Management
- Budihardjo Chandra, CEO of Genero Pharmaceuticals. PT,
- Alfons Sindupranata, President Director of Derma Global Ventura,
- Ricardo Handoko, Founder and President Director of Arya Noble

Description
An Indonesia-based CDMO specialized in pharma products, cosmetics and traditional medicines, lab and clinical testing. Being a micro-enterprise of the Derma Global Ventura (DGV) group and a part of the Arya Noble Group Company, Genero has a comprehensive understanding of the various facets related to dermatology. This extensive industry know-how has been helping the company provide leading-edge skin solutions for the last 20 years. Today, Genero is conquering the entire SEA market with its semi-solid and liquid skin formulations. Besides contract manufacturing services, Genero also provides several other services and solution to its clients. These services include product formulation, analytical method and packaging development, product stability testing, pilot scale and process validation, product registration until commercial production, and sharing of R&D, QC lab and production facilities, among others.